Yazla Ece, Kayadibi Huseyin, Cetin Ihsan, Aydinoglu Unsal, Karadere Mehmet Emrah
Department of Psychiatry, Hitit University Faculty of Medicine, Corum, Turkey.
Department of Biochemistry, Eskisehir Osmangazi University Faculty of Medicine, Eskisehir, Turkey.
Clin Psychopharmacol Neurosci. 2022 Aug 31;20(3):504-513. doi: 10.9758/cpn.2022.20.3.504.
The aim of the study was to evaluate the levels of peripheric biomarkers that have been associated with blood brain barrier (BBB) damage in healthy controls and two groups of patients with schizophrenia, those who received typical-atypical antipsychotics and those who received only atypical antipsychotics. Additionally, we sought relationships between these biomarkers and schizophrenia symptoms.
This study was conducted with the inclusion of 41 healthy volunteers and 75 patients with schizophrenia. The biomarkers measured to evaluate BBB injury were as follows: spectrin breakdown product 145 (SBDP145), spectrin breakdown product 150 (SBDP150), ubiquitin carboxy terminal hydrolase L1 (UCHL1), ubiquitin ligase cullin-3 (cullin), occludin and claudin, which were measured via ELISA. Symptoms of patients with schizophrenia were evaluated with the Scale for the Assessment of Positive Symptoms (SAPS), Scale for the Assessment of Negative Symptoms, the Clinical Global Impression Scale (CGI), and the general assessment of functionality (GAF).
Compared to controls, SBDP145 ( = 0.022) and cullin ( = 0.046) levels were significantly higher in patients with schizophrenia receiving atypical antipsychotic treatment. SBDP150 levels were lower in the combination treatment group compared to the control group ( = 0.022). Claudin ( = 0.804), occludin ( = 0.058) and UCHL1 ( = 0.715) levels were similar among groups. In recipients of combination treatment, SBDP145 levels were found to be positively correlated with SAPS-total (r = 0.440, = 0.036) and SAPS-delusions (r = 0.494, = 0.017) scores.
The relationships demonstrated in this study indicate that more comprehensive research is needed to understand whether BBB defects contribute to clinical characteristics in patients with schizophrenia.
本研究旨在评估健康对照组以及两组精神分裂症患者（接受典型-非典型抗精神病药物治疗的患者和仅接受非典型抗精神病药物治疗的患者）中与血脑屏障（BBB）损伤相关的外周生物标志物水平。此外，我们还探寻了这些生物标志物与精神分裂症症状之间的关系。
本研究纳入了41名健康志愿者和75名精神分裂症患者。用于评估BBB损伤的生物标志物如下：血影蛋白降解产物145（SBDP145）、血影蛋白降解产物150（SBDP150）、泛素羧基末端水解酶L1（UCHL1）、泛素连接酶cullin-3（cullin）、闭合蛋白和紧密连接蛋白，通过酶联免疫吸附测定（ELISA）法进行检测。采用阳性症状评定量表（SAPS）、阴性症状评定量表、临床总体印象量表（CGI）和功能综合评定量表（GAF）对精神分裂症患者的症状进行评估。
与对照组相比，接受非典型抗精神病药物治疗的精神分裂症患者的SBDP145（P = 0.022）和cullin（P = 0.046）水平显著更高。联合治疗组的SBDP150水平低于对照组（P = 0.022）。各组间闭合蛋白（P = 0.804）、紧密连接蛋白（P = 0.058）和UCHL1（P = 0.715）水平相似。在联合治疗组患者中，发现SBDP145水平与SAPS总分（r = 0.440，P = 0.036）和SAPS-妄想（r = 0.494，P = 0.017）评分呈正相关。
本研究中所展示的关系表明，需要进行更全面的研究，以了解BBB缺陷是否对精神分裂症患者的临床特征有影响。
